📊 CTKB Key Takeaways
Is Cytek Biosciences, Inc. (CTKB) a Good Investment?
Cytek Biosciences exhibits severe operational challenges with negative operating and net margins of -20% and -33% respectively, despite maintaining a healthy gross margin of 51.8%. The company is burning cash with negative free cash flow of -8.8M and negative operating cash flow, indicating unsustainable operations that will deplete the current cash position within 10+ years at current burn rates. Strong balance sheet liquidity and minimal debt provide a temporary cushion, but the core business is not generating profits and revenue growth is negligible at 0.5% YoY.
Cytek Biosciences shows a mixed fundamental profile: the company has strong gross margins, substantial liquidity, and almost no leverage, but revenue growth is essentially flat and profitability remains deeply negative. Cash burn is still relatively manageable versus its cash balance, yet the business needs clearer operating leverage and sustained improvement in margins to support a stronger fundamental outlook.
Why Buy Cytek Biosciences, Inc. Stock? CTKB Key Strengths
- Exceptional gross margin of 51.8% demonstrates pricing power and efficient manufacturing
- Strong balance sheet with $90.9M cash and minimal debt ($525K), providing runway for turnaround
- Solid liquidity position with 5.04x current ratio and 4.42x quick ratio
- Strong liquidity with a 5.04x current ratio and $90.85M in cash
- Healthy gross margin of 51.8%, indicating solid core product economics
- Very low leverage with only $525K of long-term debt and near-zero debt/equity
CTKB Stock Risks: Cytek Biosciences, Inc. Investment Risks
- Severe profitability challenge: -$66.5M net loss with negative operating income of -$40.4M signals fundamental operational issues
- Negative free cash flow of -$8.8M and negative operating cash flow indicate unsustainable cash burn despite positive gross profit
- Stagnant revenue growth at only 0.5% YoY with deteriorating EPS (-550% YoY) suggests inability to scale profitably
- Negative ROE (-19.5%) and ROA (-14.4%) indicate destruction of shareholder value
- Operating and net margins remain deeply negative at -20.0% and -33.0%
- Revenue growth of just 0.5% suggests weak growth quality and limited momentum
- Negative free cash flow and operating cash flow indicate the business is not yet self-funding
Key Metrics to Watch
- Path to operating profitability and timeline for positive EBITDA
- Operating expense reduction efforts and SG&A as percentage of revenue
- Operating cash flow trajectory and cash runway at current burn rate
- Revenue growth acceleration and gross margin sustainability
- Operating margin improvement
- Revenue growth acceleration
Cytek Biosciences, Inc. (CTKB) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 5.04x current ratio provides a solid financial cushion.
CTKB Profit Margin, ROE & Profitability Analysis
CTKB vs Industrial Sector: How Cytek Biosciences, Inc. Compares
How Cytek Biosciences, Inc. compares to Industrial sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Cytek Biosciences, Inc. Stock Overvalued? CTKB Valuation Analysis 2026
Based on fundamental analysis, Cytek Biosciences, Inc. has mixed fundamental signals relative to the Industrial sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Cytek Biosciences, Inc. Balance Sheet: CTKB Debt, Cash & Liquidity
CTKB Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Cytek Biosciences, Inc.'s revenue has grown significantly by 57% over the 5-year period, indicating strong business expansion. The most recent EPS of $0.00 indicates the company is currently unprofitable.
CTKB Revenue Growth, EPS Growth & YoY Performance
CTKB Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $51.5M | N/A | $0.01 |
| Q2 2025 | $45.6M | N/A | $-0.04 |
| Q1 2025 | $41.5M | -$6.2M | $-0.05 |
| Q3 2024 | $48.0M | N/A | $0.01 |
| Q2 2024 | $46.6M | N/A | $-0.03 |
| Q1 2024 | $37.1M | N/A | $-0.05 |
| Q3 2023 | $40.5M | N/A | $-0.01 |
| Q2 2023 | $40.2M | -$702.0K | $0.00 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Cytek Biosciences, Inc. Dividends, Buybacks & Capital Allocation
CTKB SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Cytek Biosciences, Inc. (CIK: 0001831915)
📋 Recent SEC Filings
| Date | Form | Document | Action |
|---|---|---|---|
| Mar 13, 2026 | 4 | xslF345X05/form4-03132026_100343.xml | View → |
| Mar 12, 2026 | 4 | xslF345X05/form4-03122026_080314.xml | View → |
| Mar 12, 2026 | 4 | xslF345X05/form4-03122026_080318.xml | View → |
| Mar 12, 2026 | 4 | xslF345X05/form4-03122026_080302.xml | View → |
| Mar 12, 2026 | 4 | xslF345X05/form4-03122026_080314.xml | View → |
❓ Frequently Asked Questions about CTKB
What is the AI rating for CTKB?
Cytek Biosciences, Inc. (CTKB) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (HOLD) with 80% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are CTKB's key strengths?
Claude: Exceptional gross margin of 51.8% demonstrates pricing power and efficient manufacturing. Strong balance sheet with $90.9M cash and minimal debt ($525K), providing runway for turnaround. ChatGPT: Strong liquidity with a 5.04x current ratio and $90.85M in cash. Healthy gross margin of 51.8%, indicating solid core product economics.
What are the risks of investing in CTKB?
Claude: Severe profitability challenge: -$66.5M net loss with negative operating income of -$40.4M signals fundamental operational issues. Negative free cash flow of -$8.8M and negative operating cash flow indicate unsustainable cash burn despite positive gross profit. ChatGPT: Operating and net margins remain deeply negative at -20.0% and -33.0%. Revenue growth of just 0.5% suggests weak growth quality and limited momentum.
What is CTKB's revenue and growth?
Cytek Biosciences, Inc. reported revenue of $201.5M.
Does CTKB pay dividends?
Cytek Biosciences, Inc. does not currently pay dividends.
Where can I find CTKB SEC filings?
Official SEC filings for Cytek Biosciences, Inc. (CIK: 0001831915) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CTKB's EPS?
Cytek Biosciences, Inc. has a diluted EPS of $-0.09.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is CTKB a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Cytek Biosciences, Inc. has a SELL rating with 80% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is CTKB stock overvalued or undervalued?
Valuation metrics for CTKB: ROE of -19.5% (sector avg: 15%), net margin of -33.0% (sector avg: 10%). Compare these metrics with sector averages to assess valuation.
Should I buy CTKB stock in 2026?
Our dual AI analysis gives Cytek Biosciences, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is CTKB's free cash flow?
Cytek Biosciences, Inc.'s operating cash flow is $-4.7M, with capital expenditures of $4.1M. FCF margin is -4.4%.
How does CTKB compare to other Industrial stocks?
Vs Industrial sector averages: Net margin -33.0% (avg: 10%), ROE -19.5% (avg: 15%), current ratio 5.04 (avg: 1.8).